The Student Health Service (SHS) provides the immunizations (vaccines) required for the health and safety of students and
patients on site. Detailed preregistration requirements are available in the preregistration brochures below.
Preregistration Health Requirements for Clinical Students (Dental, Medical, Nursing, Occupational Therapy, Physical Therapy)
Preregistration Health Requirements for Non-Clinical Students (Public Health, Human Nutrition, Graduate School of Arts and Sciences, Post-Doctoral Fellows)
View Health Requirements Fee Schedule
To receive immunizations, please see Elsa Cadena, R.N., who is located in the main Student Health Service office,
60 Haven Avenue, Ground Floor. If Elsa is unavailable, another nurse will assist you.
All full-time and part-time Columbia University Medical Center students are required to be immune to measles
(rubeola), mumps, and rubella as a condition of enrollment. According to New York State law, you must also
sign the Meningococcal Response Form. You may submit
this form online at registration and also via the Web Portal.
For more information on the vaccine, follow the links below.
Center for Disease
Control Vaccine and Disease Information
CDC National Center for Immunization and Respiratory Diseases (NCIRD)
Gardasil (Human Papilloma Virus Vaccine)
Gardasil vaccine is available in the SHS at no charge for those students enrolled in the Aetna Student Health Insurance Plan.
The 3 vaccine doses are given over six months according to the following schedule:
It is recommended for women ages 11-26, as well as for men having sex with men. It may also be given to men ages 11-26.
You do not need to be screened for HPV infection prior to receiving the vaccine. Ideally it is recommended for girls before they become sexually active, when it offers the most protection, but since it does cover 4 HPV types, women who have already had an HPV infection will gain protection against types they have not had. (We cannot currently test to find if you have already had one or more of the vaccine types.)
It has not yet been tested for safety and effectiveness in women over 26.
- First dose: Now
- Second dose: 2 months after Dose 1
- Third dose: 6 months after Dose 1